15 Matching Annotations
  1. Last 7 days
  2. 52.53.155.43 52.53.155.43
    ajcr0151293-html.html
    1
    1. scibot 18 Jul 2024
      CVCL_1865

      DOI: 10.62347/giir3351

      Resource: (DSMZ Cat# ACC-553, RRID:CVCL_1865)

      Curator: @scibot

      SciCrunch record: RRID:CVCL_1865

      What is this?
      RRID:CVCL_1865
    Visit annotations in context

    Tags

    Annotators

    URL

    52.53.155.43/3e506c81eb294633d25ccb146c7b74591d49000f/ajcr0151293-html.html
  3. www.ncbi.nlm.nih.gov www.ncbi.nlm.nih.gov
    Chidamide represses MYC expression and might improve survival for patients with double expressor lymphoma
    1
    1. scibot 14 Jul 2024
      RRID:CVCL_1865

      DOI: 10.62347/GIIR3351

      Resource: (DSMZ Cat# ACC-553, RRID:CVCL_1865)

      Curator: @scibot

      SciCrunch record: RRID:CVCL_1865

      What is this?
      RRID:CVCL_1865
    Visit annotations in context

    Tags

    Annotators

    URL

    ncbi.nlm.nih.gov/pmc/articles/PMC11236771/
  4. May 2024
  5. www.ncbi.nlm.nih.gov www.ncbi.nlm.nih.gov
    Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects
    1
    1. scibot 24 May 2024
      RRID:CVCL_1865

      DOI: 10.1158/2767-9764.CRC-24-0071

      Resource: (DSMZ Cat# ACC-553, RRID:CVCL_1865)

      Curator: @scibot

      SciCrunch record: RRID:CVCL_1865

      What is this?
      RRID:CVCL_1865
    Visit annotations in context

    Tags

    Annotators

    URL

    ncbi.nlm.nih.gov/pmc/articles/PMC11110724/
  6. Jan 2024
  7. www.ncbi.nlm.nih.gov www.ncbi.nlm.nih.gov
    Safety and feasibility of anti-CD19 CAR T cells expressing inducible IL-7 and CCL19 in patients with relapsed or refractory large B-cell lymphoma
    1
    1. scibot 11 Jan 2024
      CVCL_1865

      DOI: 10.1038/s41421-023-00625-0

      Resource: (DSMZ Cat# ACC-553, RRID:CVCL_1865)

      Curator: @scibot

      SciCrunch record: RRID:CVCL_1865

      What is this?
      RRID:CVCL_1865
    Visit annotations in context

    Tags

    Annotators

    URL

    ncbi.nlm.nih.gov/pmc/articles/PMC10774422/
  8. Nov 2023
  9. www.sciencedirect.com www.sciencedirect.com
    Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies
    1
    1. scibot 28 Nov 2023
      RRID:CVCL_1865

      DOI: 10.1016/j.ccell.2023.11.001

      Resource: (DSMZ Cat# ACC-553, RRID:CVCL_1865)

      Curator: @jmitrevska

      SciCrunch record: RRID:CVCL_1865

      What is this?
      RRID:CVCL_1865
    Visit annotations in context

    Tags

    Annotators

    URL

    sciencedirect.com/science/article/pii/S1535610823003665
  10. www.nature.com www.nature.com
    Preclinical evidence for the effective use of TL-895, a highly selective and potent second-generation BTK inhibitor, for the treatment of B-cell malignancies
    1
    1. scibot 25 Nov 2023
      RRID:CVCL_1865

      DOI: 10.1038/s41598-023-47735-z

      Resource: (DSMZ Cat# ACC-553, RRID:CVCL_1865)

      Curator: @scibot

      SciCrunch record: RRID:CVCL_1865

      What is this?
      RRID:CVCL_1865
    Visit annotations in context

    Tags

    Annotators

    URL

    nature.com/articles/s41598-023-47735-z
  11. Jul 2023
  12. www.ncbi.nlm.nih.gov www.ncbi.nlm.nih.gov
    Preclinical Evidence of an Allogeneic Dual CD20xCD22 CAR to Target a Broad Spectrum of Patients with B-cell Malignancies
    1
    1. scibot 08 Jul 2023
      RRID:CVCL_1865

      DOI: 10.1158/2326-6066.CIR-22-0910

      Resource: (DSMZ Cat# ACC-553, RRID:CVCL_1865)

      Curator: @scibot

      SciCrunch record: RRID:CVCL_1865

      What is this?
      RRID:CVCL_1865
    Visit annotations in context

    Tags

    Annotators

    URL

    ncbi.nlm.nih.gov/pmc/articles/PMC10320475/
  13. Apr 2023
  14. aacrjournals.org aacrjournals.org
    IOA-244 is a Non–ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance
    1
    1. scibot 19 Apr 2023
      CVCL_1865

      DOI: 10.1158/2767-9764.CRC-22-0477

      Resource: (DSMZ Cat# ACC-553, RRID:CVCL_1865)

      Curator: @scibot

      SciCrunch record: RRID:CVCL_1865

      What is this?
      RRID:CVCL_1865
    Visit annotations in context

    Tags

    Annotators

    URL

    aacrjournals.org/cancerrescommun/article/3/4/576/725855/IOA-244-is-a-Non-ATP-competitive-Highly-Selective
  15. Nov 2022
  16. www.mdpi.com www.mdpi.com
    Bcl-2 Family Members Bcl-xL and Bax Cooperatively Contribute to Bortezomib Resistance in Mantle Cell Lymphoma
    1
    1. scibot 29 Nov 2022
      RRID:CVCL_1865

      DOI: 10.3390/ijms232214474

      Resource: (DSMZ Cat# ACC-553, RRID:CVCL_1865)

      Curator: @scibot

      SciCrunch record: RRID:CVCL_1865

      What is this?
      RRID:CVCL_1865
    Visit annotations in context

    Tags

    Annotators

    URL

    mdpi.com/1422-0067/23/22/14474
  17. Oct 2021
  18. www.sciencedirect.com www.sciencedirect.com
    Lymphocyte access to lymphoma is impaired by high endothelial venule regression
    1
    1. scibot 27 Oct 2021
      ACC 553

      DOI: 10.1016/j.celrep.2021.109878

      Resource: (DSMZ Cat# ACC-553, RRID:CVCL_1865)

      Curator: @Naa003

      SciCrunch record: RRID:CVCL_1865

      What is this?
      RRID:CVCL_1865 RRIDCUR:Missing
    Visit annotations in context

    Tags

    Annotators

    URL

    sciencedirect.com/science/article/pii/S2211124721013486
  19. Aug 2021
  20. bpspubs.onlinelibrary.wiley.com bpspubs.onlinelibrary.wiley.com
    A non‐covalent inhibitor XMU‐MP‐3 overrides ibrutinib‐resistant BtkC481S mutation in B‐cell malignancies
    1
    1. scibot 01 Aug 2021
      RRID:CVCL_1865

      DOI: 10.1111/bph.14809

      Resource: (DSMZ Cat# ACC-553, RRID:CVCL_1865)

      Curator: @Naa003

      SciCrunch record: RRID:CVCL_1865

      What is this?
      RRID:CVCL_1865 RRIDCUR:Validated
    Visit annotations in context

    Tags

    Annotators

    URL

    bpspubs.onlinelibrary.wiley.com/doi/10.1111/bph.14809
  21. Jul 2021
  22. www.ncbi.nlm.nih.gov www.ncbi.nlm.nih.gov
    CAR T cells targeting αvβ3 integrin are effective against advanced cancer in preclinical models
    1
    1. scibot 30 Jul 2021
      JeKo-1

      DOI: 10.1002/acg2.11

      Resource: (DSMZ Cat# ACC-553, RRID:CVCL_1865)

      Curator: @Naa003

      SciCrunch record: RRID:CVCL_1865

      What is this?
      RRID:CVCL_1865 RRIDCUR:Missing
    Visit annotations in context

    Tags

    Annotators

    URL

    ncbi.nlm.nih.gov/pmc/articles/PMC6226260/
  23. www.sciencedirect.com www.sciencedirect.com
    ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors
    1
    1. scibot 22 Jul 2021
      CVCL_1865

      DOI: 10.1016/j.xcrm.2021.100350

      Resource: (DSMZ Cat# ACC-553, RRID:CVCL_1865)

      Curator: @scibot

      SciCrunch record: RRID:CVCL_1865

      What is this?
      RRID:CVCL_1865
    Visit annotations in context

    Tags

    Annotators

    URL

    sciencedirect.com/science/article/pii/S2666379121001993
  24. May 2021
  25. clincancerres.aacrjournals.org clincancerres.aacrjournals.org
    A Cyclin D1–Dependent Transcriptional Program Predicts Clinical Outcome in Mantle Cell Lymphoma
    1
    1. scibot 10 May 2021
      RRID:CVCL_1865

      DOI: 10.1158/1078-0432.CCR-20-2868

      Resource: (DSMZ Cat# ACC-553, RRID:CVCL_1865)

      Curator: @scibot

      SciCrunch record: RRID:CVCL_1865

      What is this?
      RRID:CVCL_1865
    Visit annotations in context

    Tags

    Annotators

    URL

    clincancerres.aacrjournals.org/content/27/1/213
  26. Mar 2021
  27. www.sciencedirect.com www.sciencedirect.com
    Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma
    1
    1. scibot 17 Mar 2021
      RRID:CVCL_1865

      DOI: 10.1016/j.celrep.2021.108870

      Resource: (DSMZ Cat# ACC-553, RRID:CVCL_1865)

      Curator: @scibot

      SciCrunch record: RRID:CVCL_1865

      What is this?
      RRID:CVCL_1865
    Visit annotations in context

    Tags

    Annotators

    URL

    sciencedirect.com/science/article/pii/S2211124721001844